GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
13 December 2023 - 12:00AM
Business Wire
- Ten projects will receive funding to help address adult
immunization gaps in communities across the country
- GSK launched the COiMMUNITY Initiative in June to help increase
adult immunization rates in the US through grant funding, increased
data transparency and resource-sharing opportunities
GSK plc (LSE/NYSE: GSK) today announced the recipients of the
inaugural grant program of the COiMMUNITY Initiative, a
multipronged effort to support the design of a more systematic,
collaborative and equitable approach to helping increase adult
immunization rates in the US. Each grant-funded project is
receiving between $50,000 and $175,000 out of a total $1 million in
funding to help address long-standing barriers to adult
immunization in the US.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231212489783/en/
Rob Truckenmiller, Senior Vice President, Head of US
Vaccines, GSK, said: “Getting ahead of vaccine-preventable
disease starts by investing in organizations who know their
communities best, and I can’t think of a more deserving group of
recipients for our first-ever COiMMUNITY Initiative grants. With
these grants, our goal is to support innovative ways to encourage
adult vaccination and help mitigate health inequities at both the
local and national levels.”
The organizations that received funding submitted proposals that
demonstrated innovative, ambitious and actionable ideas for
boosting adult vaccination, such as building vaccine confidence
among underserved patient populations through trusted community
partners, creating engaging multilingual educational materials, and
developing resources to support pharmacists and local health
departments.
Hear from some of the 2023 COiMMUNITY Initiative grant
recipients:
Liz Helms, President and CEO, California Chronic Care
Coalition, said: “A successful vaccination program can
alleviate the devastation of contagious diseases. We must meet
people where they are – both online and in real life – if we hope
to end inequities and social biases surrounding vaccine uptake.
That’s what we aim to do with this funding, and we’re grateful for
GSK’s support.”
Lisa Robertson, MPH, Executive Director, Indiana Immunization
Coalition, said: “For our vulnerable immigrant and refugee
communities, vaccination may not be top priority, and language and
financial barriers present extra hurdles. With this grant, we hope
to make vaccination more accessible to these communities by
engaging with people in their own language and sharing information
about clinics offering no-cost immunization.”
Other grant recipients include the American Lung Association,
American Pharmacists Association (APhA), APhA Foundation, Asian
Health Coalition, Global Health Living Foundation, Immunize Kansas
Coalition, Pharmacy Quality Alliance, and The Arizona Partnership
for Immunization.
Through the COiMMUNITY Initiative, GSK will continue to build on
its commitment to help support long- lasting solutions to address
adult immunization challenges through ongoing investments to
empower stakeholders with actionable data, and models and best
practices in adult vaccine confidence and delivery. These resources
can be found on VaccineTrack.com.
About GSK
GSK is a global biopharma company with a purpose to unite
science, technology, and talent to get ahead of disease together.
Find out more at gsk.com.
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors” in the company's Annual Report on Form 20-F for
2022, and Q2 Results for 2023.
Registered in England & Wales: No. 3888792
Registered Office: 980 Great West Road Brentford,
Middlesex TW8 9GS
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231212489783/en/
GSK enquiries
Kathleen Quinn +1 202 603 5003 (Washington DC)
Alison Hunt +1 540 742 3391 (Washington DC)
Investor Relations:
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024